CY1116201T1 - PROVIDING FUNCTIONAL NUCLEAR ACID IN Mammalian Cells Through Inhaled Microbial Bacterial Origin - Google Patents

PROVIDING FUNCTIONAL NUCLEAR ACID IN Mammalian Cells Through Inhaled Microbial Bacterial Origin

Info

Publication number
CY1116201T1
CY1116201T1 CY20151100364T CY151100364T CY1116201T1 CY 1116201 T1 CY1116201 T1 CY 1116201T1 CY 20151100364 T CY20151100364 T CY 20151100364T CY 151100364 T CY151100364 T CY 151100364T CY 1116201 T1 CY1116201 T1 CY 1116201T1
Authority
CY
Cyprus
Prior art keywords
mammalian cells
bacterial origin
microbial bacterial
providing functional
nuclear acid
Prior art date
Application number
CY20151100364T
Other languages
Greek (el)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20110171410 external-priority patent/EP2386640B1/en
Application filed by Engeneic Molecular Delivery Pty Ltd. filed Critical Engeneic Molecular Delivery Pty Ltd.
Publication of CY1116201T1 publication Critical patent/CY1116201T1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Άθικτα, βακτηριακά προερχόμενα μικροκύτταρα που περιέχουν ένα μόριο λειτουργικού νουκλεϊκού οξέος ή πλασμίδια που κωδικοποιούν λειτουργικά νουκλεϊκά οξέα μπορούν να μειώνουν, σε στοχευόμενα κύτταρα θηλαστικών, την αντίσταση φαρμάκου, αντίσταση απόπτωσης και νεοπλαστικότητα, αντίστοιχα. Μεθοδολογία που χρησιμοποιεί μικροκύτταρα για παροχή λειτουργικών νουκλεϊκών οξέων, που στοχεύουν τα μεταγραφήματα πρωτεϊνών που συμβάλλουν στην αντίσταση φαρμάκου ή αντίσταση απόπτωσης, μεταξύ άλλων, μπορούν να συνδυάζονται με χημειοθεραπεία για αύξηση της αποτελεσματικότητας της χημειοθεραπείας.Intact, bacterial-derived microcytes containing a functional nucleic acid molecule or plasmids encoding functional nucleic acids can reduce drug resistance, apoptosis resistance, and neoplasm, respectively, in target mammalian cells. A methodology that utilizes microcytes to deliver functional nucleic acids, which target protein transcripts that contribute to drug resistance or apoptosis resistance, may, inter alia, be combined with chemotherapy to increase the efficacy of chemotherapy.

CY20151100364T 2004-08-26 2015-04-20 PROVIDING FUNCTIONAL NUCLEAR ACID IN Mammalian Cells Through Inhaled Microbial Bacterial Origin CY1116201T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60443304A 2004-08-26 2004-08-26
EP20110171410 EP2386640B1 (en) 2004-08-26 2005-08-25 Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells

Publications (1)

Publication Number Publication Date
CY1116201T1 true CY1116201T1 (en) 2017-02-08

Family

ID=58457938

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100364T CY1116201T1 (en) 2004-08-26 2015-04-20 PROVIDING FUNCTIONAL NUCLEAR ACID IN Mammalian Cells Through Inhaled Microbial Bacterial Origin

Country Status (1)

Country Link
CY (1) CY1116201T1 (en)

Similar Documents

Publication Publication Date Title
WO2006021894A3 (en) Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
Komander et al. The ubiquitin code
CY1118437T1 (en) Targeted Release of Therapeutic Nucleic Acids and Functional Nucleic Acids in Mammalian Unconventional Thyroid Cells
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
CY1116417T1 (en) CULTIVATING WITH IMPROVED LIGHT RESISTANCE
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
CY1112924T1 (en) JNK Cell Signaling Disruptions
AR088513A1 (en) IMMUNO LINKERS AGAINST SCLEROSTINE
AR068347A1 (en) HUMAN C-FMS ANTIGEN UNION PROTEINS
UY31543A1 (en) SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
MX2021010668A (en) Cytokine fusion proteins.
NZ602220A (en) Antibodies with ph dependent antigen binding
EA200802184A1 (en) PHARMACEUTICAL COMPOSITIONS WITH DPP IV INHIBITORS
TR201910686T4 (en) Lipid nanoparticle compositions and methods for Mrna delivery.
BRPI0600115A (en) systems and methods for regulating preload current in a battery system
NZ750556A (en) Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
MX2010005451A (en) System for delivery into a xcr1 positive cell and uses thereof.
WO2011020089A3 (en) Target genes for cancer therapy
CL2012002879A1 (en) Recombinant robo1-fc protein comprising the extracellular domain of the isoform b of the robo1 protein or a part of this domain, a linker and an fc domain of an immunoglobulin; nucleic acid molecule that encodes it; pharmaceutical composition comprising it; and its use as a diagnostic tool to detect overexpression of a molecule of the slit family in a patient.
BRPI0815094B8 (en) USE OF A MOLECULE OF L-NUCLEIC ACID ATTACHED TO SDF-1
BR112012029280A2 (en) serum antialbumin immunoglobulin single variable domain variant, anti-sa immunoglobulin, multispecific ligand, fusion protein, composition, nucleic acid, vector, isolated host cell, and use of one variant, multispecific ligand or fusion protein
AR086473A1 (en) SYNTHETIC FITASA VARIANTS
MX2017009272A (en) Cell penetrating antibodies.
UA95446C2 (en) Mutations in oas1 genes
MX2009009700A (en) Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same.